Latest Administration News

SDI Limited’s acquisition by Beijing Guoci subsidiary is now effective following New South Wales Supreme Court approval, with the ASX suspension commencing and cash payout scheduled for early July.

The a2 Milk Company has announced a $300 million fully franked special dividend following regulatory clearance in China to rebrand infant formula products under its a2 label.

EROAD Limited reported stable FY26 revenue of NZD 195 million amid a $134.7 million North American impairment, unveiling a strategic reset centred on ANZ growth and its expanding electronic Road User Charges platform.

Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.

The Calmer Co. has won Coles' approval for its innovative Fiji Kava® FZZR™ product, extending its Australian supermarket reach while gearing up for a broader U.S. retail rollout supported by a key brokerage partnership.

Constellation Resources is raising $3.22 million through a non-renounceable entitlement offer priced at $0.12 per share, aiming to bolster exploration in Western Australia and support general working capital.

LE Minerals has significantly expanded its White Plains Lithium Brine Project in Utah by securing an additional 2,340 hectares of mineral leases, boosting its total landholding to around 8,520 hectares. The company now holds exclusive rights to explore lithium and other mineral salts for three years, with the option to enter a 10-year extraction lease thereafter.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

CONNEQT Health has lodged an FDA Pre-Submission for SphygmoCor Cloud, aiming to shift its arterial health analytics from hardware to a scalable software platform with broad commercial potential.

Transurban and NSW Government will replace paper toll notices with digital alerts, removing administration fees and streamlining unpaid toll enforcement on Sydney roads from July 2026.

Recce Pharmaceuticals has secured ethics approval to upgrade and broaden its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, accelerating recruitment and reinforcing its global registration ambitions.

Emyria has trained its first cohort of 31 clinicians in New South Wales, paving the way for its inaugural Sydney Empax clinic at Matilda Nepean, scheduled to open in Q3 2026.